ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win
Pfizer's Braftovi, combined with Eli Lilly's Erbitux and chemo, won an accelerated approval last year through the FDA's Project FrontRunner. Now, the company is working toward a potential full approval.
Pfizer's Braftovi, combined with Eli Lilly's Erbitux and chemo, won an accelerated approval last year through the FDA's Project FrontRunner. Now, the company is working toward a potential full approval.
